-
Document de presse | 2021.07.12
Ivermectin alleviates Covid-19 symptoms in an animal model
Since the start of the COVID-19 pandemic, various therapeutic approaches have been explored to tackle the disease. Scientists from the Institut Pasteur have shown that ivermectin, a drug used commercially as an antiparasitic treatment, offers protection from COVID-19 symptoms in an animal model. The scientists observed that taking ivermectin was associated with reduced inflammation in the...
-
Report | 2024.03.12
COVID-19: which monoclonal antibodies should be used for vulnerable individuals?
Vaccination does not offer sufficient protection against severe forms of COVID-19 for people with a weakened immune system. For these individuals, monoclonal antibodies have long been the preferred therapeutic solution. But depending on the SARS-CoV-2 variant, the effectiveness of these treatments has fluctuated. Scientists have had to develop novel antibodies that are more effective while also...
-
News | 2020.06.18
COVID-19: the latest on the epidemic situation and why caution is still needed
On June 8, the Director-General of the World Health Organization stated that although the COVID-19 epidemic situation is improving in Europe, globally it is worsening, and we must avoid lapsing into complacency. The situation is a complex one. The Institut Pasteur provides a brief summary of the latest developments. What are the current key issues, what monitoring indicators are being used, how...
-
Article | 2020.06.16
Randomized trial of Covid-19 chemoprophylaxis in healthcare professionals
Objective: To determine whether a two months treatment with hydroxychloroquine (HCQ) or Lopinavir / ritonavir (LPV / r) reduces the incidence of symptomatic or asymptomatic infections with SARS-CoV-2, compared to their placebo, in healthcare professionals exposed to the virus.In the absence of specific antiviral treatment, particular attention must be paid to prevention. Individual protective...
-
Document de presse | 2021.02.12
Comment: The tortuous path to ending the Covid-19 pandemic
The COVID-19 pandemic has devastated health-care systems, shut down schools and communities, and plunged the world into an economic recession. While 2020 was a challenging year, 2021 looks to be difficult with the emergence of multiple variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The race to vaccinate the world will need to respond to the pathogen's constant evolution...
-
Document de presse | 2021.08.26
COVID-19: Will telecommuting strategies stop the virus from circulating?
How can we best organise on-site workplace and school attendance periods and remote work to slow the circulation of Sars-CoV-2? Is it better to separate classes? Bring your whole team in at the same time? Set this up on daily or weekly schedules? The COVID-19 pandemic has forced most countries to impose contact limitations in workplaces, universities and schools. Scientists from the CNRS,...
-
News | 2022.09.05
COVID-19: we are looking for volunteers to improve our understanding of immunity
We are looking for volunteers to take part in the CORSER-5 study. The study was launched in March 2022 to compare the immunity of COVID-19-positive individuals at the very beginning of their infection period ("cases") with that of non-infected individuals ("controls"). The results could be used to establish a booster vaccination strategy for SARS-CoV-2 on the basis of patients' antibody...
-
News | 2021.01.25
Covid-19: impacts of the pandemic on the human microbiome
The Covid-19 epidemic has had great impact on people’s lives across the world. The disease, physical distancing and lockdown measures have had multiple effects on health. One less-studied effect is the consequence on the microbiome. A group of prominent microbiome researchers in biomedical and social science, coordinated by Brett Finlay (University of British Columbia) and Tamara Giles-Vernick (...
-
Article | 2020.10.14
Covid-19: A vaccine candidate using a lentiviral vector
This vaccine candidate for the SARS-CoV-2 virus, designed for nasal administration, demonstrated intense protection and extremely high production of antibodies and cytotoxic cell responses in preclinical trials.
-
Document de presse | 2021.02.26
Covid-19: Keeping schools as safe as possible
A year into the pandemic, and confronted with continued resurgence in transmission, over 800 million schoolchildren, more than half the world’s student population, still face substantial disruptions to their education. These range from full school closures in 31 countries to reduced or part time academic schedules in another 48 countries. Some countries, such as Norway and France, chose largely...
